Neuro- and Hepatoprotective Effects of Methylene Blue in Rats Treated with Lipopolysaccharide Endotoxin
Keywords:Brain injury; Lipid peroxidation; Lipopolysaccharide; Liver injury; Methylene blue
The effects of methylene blue (MethyB) on oxidative stress markers in the serum and on the brain and liver tissue damage following lipopolysaccharide (LPS) injection in rats were studied. Rats received intraperitoneal (i.p.) injection of LPS (300 µg/kg) alone or along with MethyB (5 and 10 mg/kg) and euthanized 4 h later. Malondialdehyde (MDA), nitric oxide, paraoxonase-1 (PON-1) activity, cholinesterase activity, and glucose were measured in the serum. The brain and liver histopathology, glial fibrillary acidic protein (GFAP), and caspase-3 immunostaining in the brain were performed. Results indicated that LPS treatment caused significantly raised MDA and nitric oxide concentrations by 52.8% and 47.5%, respectively. Cholinesterase activity was not significantly changed, but PON1 activity fell by 48.1%. Serum glucose increased by 48.7%. When administered to LPS-injected rats, MethyB resulted in significant decreases in serum MDA and nitric oxide concentrations, respectively. PON-1 activity increased by 37.8-89.3%, cholinesterase activity decreased by 33.4-41.2%, and serum glucose decreased by 39.6% uponMethyB treatment. Neurodegeneration, increased capsase-3 staining, decreased GFAP immunostaining in the brain and vacuolar degeneration and inflammatory cell infiltrates in the liver of LPS-treated rats were almost prevented by MethyB. These data suggest that MethyB exerts an antioxidant action and ameliorates brain and liver tissue damage during endotoxemia.
How to Cite
Submission of an original manuscript to the Journal will be taken to mean that it represents original work not previously published; that it is not being considered elsewhere for publication; that the author(s) agrees to assign copyright to the Journal upon acceptance for publication in the Journal, and if accepted for publication, it will be published in the digital format (PDF) and/or in print and it will not be published elsewhere in the same form, for commercial purposes, in any language, without the consent of the Publisher.